@article{Škof_Mangaroski_2020, title={Our experience with bevacizumab in first-line treatment of epithelial ovarian cancer}, volume={24}, url={https://revijaonkologija.si/Onkologija/article/view/441}, DOI={10.25670/oi2020-003on}, abstractNote={<p><strong>Introduction: </strong>Bevacizumab is used in advanced epithelial ovarian cancer patients as a part of standard primary sistemic therapy together with paclitaksel and carboplatin combination chemotherapy since 2013.<br><strong>Aim of study: </strong>To evaluate safety and efficacy of bevacizumab in treatment of patients with advanced epithelial ovarian cancer in daily clinical practice.<br><strong>Methods: </strong>Retrospective analysis of patients with advanced epithelial cancer treated with bevacizumab at Institute of Oncology Ljubljana in the period of Jan 1<sup>st</sup> 2013 – Dec 31<sup>th</sup> 2016. The end points of study were safety and efficacy (relapse-free survival, overall survival). Study has been approved by our institutional ethic board.<br><strong>Results: </strong>In the observed period overall 111 patients with advanced epithelial ovarian cancer were treated with bevacizumab. The most common adverse events were: pain (52%), bleeding (45%), arterial hypertension (44%). Serious adverse events (grade 3/4) were observed in 12% of patients: 3% venous thrombosis/embolism, 3% proteinuria, 2% arterial hypertension, 2% bleeding, 1% pain, 1% fistula. Median follow up was 59 months. Median progression-free survival was 18 months, median overall survival was  41 months.<br><strong>Conclusions: </strong>Treatment with bevacizumab in daily clinical practice is safe and effective – in concordance with published data from prospective studies GOG 218 and ICON 7.</p>}, number={1}, journal={Onkologija : a medical-scientific journal}, author={Škof, Erik and Mangaroski, Dušan}, year={2020}, month={May}, pages={20–24} }